Combining urinary complement biomarkers including C3a, C5a, and soluble C5b-9 (sC5b-9) with established kidney disease markers such as albuminuria, eGFR slope, and tubural injury proteins (e.g., NGAL) may help to identify patients with intrarenal complement activation who are at a higher risk for disease progression. This evidence concerns the gene C5 and kidney disorder.